Cencora (COR) is significantly outperforming its medical peers, with a year-to-date return of 29.6% compared to the Medical group's average loss of 5.3%; this is further supported by a 2.9% increase in the Zacks Consensus Estimate for full-year earnings over the past 90 days, resulting in a Zacks Rank #2 (Buy). Catalyst Pharmaceutical (CPRX) is another medical stock outperforming the sector with a 19.6% year-to-date return and a Zacks Rank #2 (Buy), making both stocks potentially attractive for investors interested in the Medical sector.
Cencora (COR) has demonstrated significant market outperformance year-to-date, delivering a 29.6% return, which starkly contrasts with the Medical group's average loss of 5.3% and its specific Medical Services industry's 3.9% decline. This robust performance is underpinned by a Zacks Rank of #2 (Buy), reflecting positive analyst sentiment as evidenced by a 2.9% upward revision in its full-year earnings consensus estimate over the past 90 days. The Zacks Rank system emphasizes earnings estimates and estimate revisions, indicating a favorable outlook for COR over the next one to three months. Similarly, Catalyst Pharmaceutical (CPRX) has also outpaced the broader Medical sector, achieving a 19.6% year-to-date return. This is supported by its own Zacks Rank #2 (Buy) and a 2.7% increase in its current year EPS consensus estimate over the past three months. Catalyst Pharmaceutical's Medical - Drugs industry, while performing slightly better than the overall Medical group, still recorded a 1.8% loss year-to-date, further underscoring CPRX's individual strength. Both companies are notable performers within the Medical sector, which itself is ranked #4 out of 16 Zacks Sector Ranks, suggesting relative strength within this broader market segment.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
